Literature DB >> 25461612

Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients.

Zhang-Yan Guo1, Yong-Gang Lv2, Lei Wang3, Sheng-Jia Shi1, Fan Yang4, Guo-Xu Zheng1, Wei-Hong Wen5, An-Gang Yang6.   

Abstract

HLA-G and HLA-E are non-classical HLA Ib molecules. Recently, increasingly more reports have shown that HLA-G is highly expressed in different malignancies. In this article, we detected the expression levels of HLA-G and HLA-E in primary colorectal cancer patients. Our results showed that 70.6% and 65.7% of the colorectal cancer tissues had positive HLA-G or HLA-E expression, respectively, and that 46.1% positively expressed both molecules. We also analyzed the correlations between the expression levels of HLA-G, HLA-E or both combined and the clinical outcomes of the patients. Kaplan-Meier analysis results showed that the expression levels of HLA-G or HLA-E alone and the combined expression of both molecules were all statistically correlated with the overall survival of colorectal cancer patients. Cox multivariate analysis showed that only HLA-G expression can serve as independent factor for OS. Our results also showed that the expression of HLA-E was significantly correlated with tumor metastasis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal carcinoma; HLA-E; HLA-G; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 25461612     DOI: 10.1016/j.cellimm.2014.10.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  39 in total

Review 1.  Cancer treatment and the KIR-HLA system: an overview.

Authors:  Patrizia Leone; Valli De Re; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Clin Exp Med       Date:  2017-02-10       Impact factor: 3.984

Review 2.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

3.  Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.

Authors:  Claudia Lennicke; Jette Rahn; Jürgen Bukur; Falko Hochgräfe; Ludger A Wessjohann; Rudolf Lichtenfels; Barbara Seliger
Journal:  Oncoimmunology       Date:  2016-12-21       Impact factor: 8.110

4.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.

Authors:  Takahiro Kamiya; See Voon Seow; Desmond Wong; Murray Robinson; Dario Campana
Journal:  J Clin Invest       Date:  2019-03-12       Impact factor: 14.808

Review 5.  Narrative review of the relationship between the maternal-fetal interface immune tolerance and the onset of preeclampsia.

Authors:  Fangyuan Luo; Jun Yue; Lingling Li; Jie Mei; Xinghui Liu; Yu Huang
Journal:  Ann Transl Med       Date:  2022-06

6.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 7.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

8.  Prognostic and Clinicopathological Value of Human Leukocyte Antigen G in Gastrointestinal Cancers: A Meta-Analysis.

Authors:  Yongjia Peng; Jian Xiao; Wenyun Li; Shuna Li; Binbin Xie; Jiang He; Chaoqun Liu
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

9.  HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Authors:  Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.